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Abstract 
Hospitalization is known to occur frequently in the first 6 months following liver transplantation 
(LT). Using a novel data linkage between the Scientific Registry of Transplant Recipients and 
Centers for Medicare and Medicaid Services, our study has two objectives: (i) determine risk 
factors for “early” hospitalization (i.e., within 6 months of LT) (ii) quantify the importance of 
hospitalization history in the first 6 months with respect to subsequent patient survival (i.e., 
survival, conditional on surviving 6 months post-LT). Methods: The study population consisted 
of patients aged ≥18 years who underwent deceased donor LT between January 1, 2003, and 
December 31, 2010, with Medicare as primary or secondary insurance and were discharged alive 
from the index LT hospitalization (n = 7,220). Results: The early hospitalization rate was 2.76 
per patient-year and was significantly associated with many recipient factors (e.g., recipient age, 
hepatitis C, diabetes, poor renal function including dialysis and recipient of TIPSS procedure 
before LT), as well as donor race and donation after cardiac death (DCD).  Conditional on 
surviving 6 months post-LT, the covariate-adjusted death rate increased by 22% for each 
additional hospitalization occurring in the first 6 months (HR=1.22; p<0.001). Conclusions: 
Several LT recipient factors are significantly associated with early hospitalization. Moreover, a 
patient’s hospitalization profile during follow-up months 0-6 is a very strong predictor of 
survival thereafter. Efforts and resources should be devoted towards identifying LT recipients at 
risk for early hospitalization and modifying the actionable risk factors such as hepatitis C, 
diabetes and BMI to improve resource utilization and overall outcomes.  
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Introduction 
Hospitalization after a surgical procedure or discharge following a medical condition 
such as pneumonia or congestive heart failure adds significantly to morbidity and mortality.(1) 
Consequently, reduction of hospital readmission has become a new target for quality 
improvement.(2) As part of the Affordable Care Act (ACA), the Centers for Medicare and 
Medicaid Services (CMS) are directed to push hospitals to reduce 30-day readmission rates via 
reduction in payments to hospitals for acute care readmission within 30-days of discharge as 
opposed to longer time periods.(2) Transplant procedures are not included in the ACA mandate 
since transplant procedures are completely different and more complex than any other surgical 
procedures or medical conditions. Furthermore, hospitalizations within 6 months of index 
transplantation (“early” hospitalization) are common and may directly or indirectly affect patient 
outcomes, quality of care and healthcare costs.  
The estimated per-patient cost for deceased donor LT is more than $500,000 for the first 
year, amounting to greater than $3 billion in total annual costs.(3) Post-LT discharges and 
hospitalization within 180 days contribute significantly to such cost.(3) Rates of post-LT 
hospitalization are not accurately known. Most of the research pertaining to hospitalization per se 
has focused on hard outcomes such as in-patient mortality or 30-day mortality. The majority of 
published data on post-LT hospitalization incidence and associated risk factors are from single 
center studies and, hence, lack generalizability and precision. (4-6)  
Systematic examination of the association of recipient, donor and transplant factors with 
early hospitalization is important, in order to understand the primary drivers of early 
hospitalization so that evidence-based point of care interventions can be developed; such 
interventions would be expected to improve outcomes and quality.  We aimed to estimate the 
incidence rates of early hospitalization and to determine the risk factors associated with early 
post-LT hospitalization rates. To carry out our objectives, we linked data from the Scientific 
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Registry for Transplant Recipients (SRTR) and Centers from Medicare and Medicaid Services 
(CMS). (7) Furthermore, we examined the impact of early hospitalization rates on patient 
survival conditional upon surviving the first six months post-LT.   The novelty in our study 
chiefly derives from (a) the study cohort; a linkage of two widely known national databases that 
are commonly used, but not often combined (b) determination of risk factors for early 
hospitalization among LT patients (c) explicit use of early hospitalization history as a predictor 
of subsequent survival. 
 
Methods 
Patient Data and Source:  
Clinical, demographic and claims information for adult patients who received LT 
between 2003 and 2010 was obtained from the SRTR and linked with CMS claims data. To 
allow for appropriate longitudinal follow-up, the population was limited to those enrolled in 
Medicare at LT and discharge from the index LT hospitalization. 
This study used data from the SRTR. The SRTR data system includes data on all donor, 
wait-listed candidates, and transplant recipients in the US, submitted by the members of the 
Organ Procurement and Transplantation Network (OPTN), and has been described elsewhere. 
The Health Resources and Services Administration (HRSA), U.S. Department of Health and 
Human Services provides oversight to the activities of the OPTN and SRTR contractors. The 
SRTR database has a uniform structure based on transplant candidate registration information 
provided by each transplant center at the time of placement on the wait-list; transplant recipient 
registration information provided by the transplant center at the time of LT; and transplant 
follow-up provided by the transplant center at six months, one year, and annually thereafter. The 
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SRTR supplements information on vital status with data on deaths from the Social Security 
Death Master Files and CMS, and for data on ESRD from CMS.(8)  
CMS hospital claims files contain enrollment and utilization data for each beneficiary. It 
also has a beneficiary summary file, as well as outpatient and inpatient claims data. The 
MedPAR File contains inpatient hospital and skilled nursing facility (SNF) final action stay 
records. Each MedPAR record represents a stay in an inpatient hospital or SNF. Each MedPAR 
record may represent one claim or multiple claims, depending on the length of a beneficiary's 
stay and the amount of services used throughout the stay. The MedPAR file includes the 
diagnosis (ICD-9 diagnosis), procedure (CPT procedure code), diagnosis related group, dates of 
admission, dates of discharge, reimbursement amount, hospital provider and beneficiary 
demographic information  
Data Linkage:  
A list of adult deceased donor LT recipients from 2003 – 2010 was sent from SRTR to 
CMS-Contractor Buccaneer to link the SRTR records with the CMS data. The linkage was 
performed based on: social security number, first and last name, sex, and date of birth. 
Buccaneer produced a crosswalk file that allowed us to match records in SRTR and CMS data 
using de-identified patient identifiers as described previously.(7) 
 This study was approved by the University of Michigan Institutional Review Board. 
Cohort Determination:   
The study included adult deceased donor recipients ≥18 years of age who underwent LT 
between January 2003 and December 2010 in the United States and were discharged alive 
without re-LT from the index LT hospitalization (n=7,220). We excluded recipients of living 
donor LT or multi-organ transplant including simultaneous liver and kidney transplant recipients, 
as well as patients with non-Medicare insurance.    
Analytic Approach:  
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Descriptive statistics for continuous variables were expressed as median (interquartile 
range) and categorical variables were expressed as counts and percentages. Unadjusted rates of 
post-LT hospitalization were expressed as admissions per-patient year. Patients were followed 
from the time of discharge from the index hospitalization (during which LT occurred) to death or 
loss to follow-up. Covariate missingness for the SRTR data varied from 0-9%. The exception 
was serum sodium (21% missingness), which was not consistently available in the SRTR prior to 
10/31/2004; hence, this covariate was not included in the models. We tested missingness as a 0/1 
indicator variable for each covariate, with non-significant missingness indicators then dropped 
from the final model. Note that results of a sensitivity analysis using complete case analysis (i.e., 
including patients with no missingness for any covariate) were consistent with the main results 
reported here.  
Modeling of Early Hospitalization Rate: 
We focused on early hospitalizations (defined as hospitalizations within the first six 
months of LT) due to their relatively high frequency of occurrence, and their potential 
association with recipient, donor, and transplant factors. We used a proportional rates  model to 
examine associations between recipient, donor and transplant characteristics and the rate of early 
hospitalization.(9) The proportional rates model is essentially an extension of the Cox model that 
accommodates recurrent events (i.e., events that can occur repeatedly for a patient; e.g., 
hospitalizations).  Like the Cox model, the proportional rates model is quite flexible; the shape of 
the baseline rate (over follow-up time) is not specified, nor is the nature of the dependence 
structure of events within-patient. Note that hospitalizations for a given patient are not assumed 
to be independent; standard errors for the rate ratios are based on a robust (sandwich) variance 
estimator that accounts correlation among events within-subject, without assuming a particular 
structure for said correlation.  
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The following recipient factors were examined: age, gender, race/ethnicity, body mass 
index (BMI), diagnosis, on life support, hospitalization/ICU status, diabetes, ascites, albumin, 
creatinine, bilirubin, international normalized ratio (INR) of prothrombin time, dialysis, status 1, 
portal vein thrombosis and history of transjugular intrahepatic portosystemic shunt (TIPSS). The 
following donor and transplant factors were included: donor age, donor gender, donor 
race/ethnicity, height, donation after cardiac death (DCD), shared organ, cold ischemia time, 
donor cause of death and split liver. We also calculated the donor risk index (DRI) for 
descriptive purposes as described previously.(9, 10) Transplant center was adjusted for using 
stratification. 
Three separate models of hospitalization stratified by transplant center were used to 
examine associations between recipient factors at LT and early post-LT hospitalizations, 
adjusting for donor and transplant related factors. The first model was adjusted for recipient and 
donor factors; the second model replaced the recipient factors with the MELD score; and the 
third model replaced the recipient factors with renal risk index (RRI). The RRI was calculated 
using the equation from Sharma et al.(11)(https://rri.med.umich.edu(12)).   
Conditional Survival Modeling: 
Next, we examined the effect of hospitalization on post-LT mortality using Cox 
regression. To be specific, the Cox model being fitted here evaluates the effect of the various risk 
factors on survival beyond 6 months, conditional on survival to the 6-month post-LT mark.  The 
focus in this model was the impact of the early (i.e., first 6 months following LT) hospitalization 
on subsequent conditional survival (i.e., given survival of the patient through the “early” post-LT 
period).   These models all included the individual recipient, donor and transplant factors 
mentioned above. This model was adjusted for recipient, donor and transplant factors, as well as, 
the number of hospitalizations within the first 6 months after discharge from the LT 
hospitalization and stratified by transplant center, in order to flexibly adjust for center effects.   
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All statistical analyses were carried out using SAS (v9.4; SAS Institute: Cary, NC). 
Results with a two-sided p-value <0.05 were considered statistically significant. 
Results 
Cohort description:  
 There were 38,041 adult recipients of deceased donor liver only transplants in the United 
States during the study period. Of these, 9,753 recipients had Medicare coverage for their 
transplant and at the time of discharge from the index transplant hospitalization. We excluded 
136 subjects who received a previous transplant, 740 for death or graft failure during index LT 
hospitalization, and 1,657 without a transplant hospitalization record bracketing the date of the 
transplant. The final study group consisted of 7,220 recipients. 
 Characteristics of recipients at the time of LT are summarized in Table 1. The median age 
at LT was 59 years (Q1: 52; Q3: 66), 66% were males, 74% were Caucasians, 36% had hepatitis 
C, and 28% had history of diabetes. The median donor risk index (DRI) was 1.45 (Q1:1.22; Q3: 
1.75).  
Hospitalization rates by post-LT follow-up time:  
 Figure 1 shows the hospitalization rates by follow up time. The hospitalization rate was 
highest in the first six months after LT (2.76 hospitalizations per patient-year) and decreased 
quickly over time to less than one hospitalization per patient-year beyond the first post-LT year. 
In the first six months after discharge from the LT hospitalization, 3,021 (42%) of patients had 
no hospitalization, 1,972 (27%) had one hospitalization, 1,055 (15%) had two hospitalization, 
and 1,172 (16%) had three or more hospitalizations (Figure 2).   
 The primary reasons recorded for early hospitalizations were allograft-liver related (28%) 
followed by infections (14%), renal complications (11%), gastrointestinal complications (9%), 
cardiovascular complications (5%), and other medical complications (32%).  
Risk factors for early hospitalization:    
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Table 2 shows the results of the adjusted model using recipient, donor and transplant 
factors as predictors of early hospitalization. Hepatitis C, diabetes, poor renal function including 
dialysis, and recipient of TIPSS procedure before LT independently predicted higher early 
hospitalization rates after adjusting for donor and transplant factors (Table 2).  
MELD score and early hospitalization: 
MELD score was significantly associated with the rate of early hospitalization when it 
replaced the individual recipient factors in the model described above. Recipients transplanted at 
MELD scores 23-29 and 30-40 had 15% (rate ratio [RR]=1.15; p=0.005) and 23% (RR=1.23; 
p<0.001) higher rates of early hospitalization, respectively, compared to those transplanted at 
MELD scores 16-18 at LT. Of the three MELD components, only serum creatinine was 
significantly associated with the rate of early hospitalization (RR=1.27; p<0. 001) when 
separately included in the model (Table 2) (RR=1.22; p<0. 001).  
RRI score and early hospitalization: 
Higher RRI was associated with a higher rate of early hospitalization (RR=1.03; 
p<0.001) after adjusting for donor and transplant factors. Among RRI components, diabetes 
(RR=1.18; p<0.001), renal function at LT (loge(Creatinine): RR=1.22; p<0.001 and dialysis: 
RR=1.29; p=0.002), loge(albumin) (RR=0.83, p=0.008), and history of TIPSS procedure 
(RR=1.10; p=0.05) were each associated with higher rates of early hospitalization.  
Results based on conditional survival: 
 Table 3 shows the independent predictors of mortality conditional upon survival at 6 
months after discharge from LT hospitalization. The adjusted relative risk of mortality increased 
by 22% with every additional hospitalization (HR=1.22; p<0.001). Being in the hospital at the 6 
month post-LT follow-up point (compared to not) was associated with 2.3-fold higher risk of 
death.  Additional factors significantly affecting mortality (conditional on 6-month survival) 
include race (African-Americans being at 38% higher death risk: HR=1.38, and Hispanic/Latino 
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being 34% lower risk: HR=0.66), BMI, Hepatitis C (HR=1.59), Hepatocellular carcinoma 
(HR=1.69), recipient on life support (HR=1.72), presence of ESRD at 6 months (HR=1.85), INR, 
and albumin. With respect to donor factors, increasing age, death due to cerebrovascular accident 
and regional share each significantly increased the death rate conditional on 6-month post-LT 
survival. 
Figure 3 displays overall survival curves for a hypothetical reference-covariate patient; 
i.e., a LT recipient whose characteristics are described by the reference level of each categorical 
predictor listed in Table 3, and 0 for each continuous predictor; since all continuous predictors 
are scored on the natural log scale, the reference level equals 1. With respect to the horizontal 
(time) axis, time 0 represents 6 months post-LT, with the hospitalization counts pertaining to the 
first 6 months of follow-up.   It can be seen that, all else equal, conditional survival depends 
strongly on a patient’s hospitalization experience during the first 6 post-LT months.  For 
instance, a patient not hospitalized in the first 6 months is estimated to have 5-year survival of 
approximately 90%. In contrast, a recipient with 6 prior hospitalizations has 5-year survival 
probability of ≈60% (Figure 4).   
 
Discussion 
This is the one of the first studies to examine the burden of all-cause hospitalization and 
its impact on patient outcomes among LT recipients at the national level. In the population of LT 
recipients with Medicare as primary or secondary insurance, hospitalization rates were highest in 
the first six months after LT and declined to a plateau after the first post-transplant year. 
Importantly, a higher rate of early hospitalization was the most significant independent predictor 
of mortality beginning six months after LT. Out of all the independent recipient factors for early 
hospitalization, diagnosis of hepatitis C, diabetes and high BMI are the most actionable and 
modifiable risk factors identified in our study.  
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Although directly acting antiviral agents (DAA) have revolutionized the treatment for 
hepatitis C with excellent response rates among patients with compensated and decompensated 
cirrhosis as well as in post-transplant setting, (13-17) hepatitis C still remains the leading 
indication for LT in the current period(18). Based upon a recent modeling study, it has been 
proposed that with the implementation of birth cohort testing for hepatitis C and the availability 
of highly effective therapies, hepatitis C could become a rare disease in the next twenty two 
years.(19) Biggins et al. found that the rates of new registrations for hepatitis C without HCC 
that were born from 1941-1955 are expected to decline, with projected stability of rates in those 
born 1956-1960. But those with hepatitis C with hepatocellular carcinoma the rates of new 
registrations are expected to be steady in patients born from 1941-1950, and projected to increase 
in patients born from 1951-1960.(20)  Our results show that hepatitis C is an important risk 
factor for early hospitalizations. With the effectiveness of DAA, hepatitis C is now a potentially 
modifiable risk factor. If these patients are treated while on the waiting list or shortly after LT it 
is possible that the risk of early hospitalization associated with hepatitis C may reduce over time.  
Our study did not examine whether the diabetes was controlled or uncontrolled in these 
patients because of the lack of availability of more granular data. However, good control of 
diabetes may affect the early hospitalization rates after LT. Similarly, there was a trend towards 
higher hospitalization in those with higher BMI. Our study also showed that higher MELD score 
and RRI score at transplant were associated with a higher rate of early hospitalization.(6, 21) 
RRI is a risk score that predicts the risk of ESRD and ESRD is an independent predictor 
hospitalization.(11) Since incident ESRD after LT is associated with high hospitalization 
rates(7), it could be plausible that ESRD status during the first six months instead of RRI may 
have accounted for the hospitalization.  
Since 2009, many studies used the 30-day cut off for early hospitalization because 
readmission over longer period of time (i.e. 60 days or 120 days) are less likely to be related to 
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index hospitalization for a medical condition or surgical procedure.  However, solid organ 
transplantation is very different from any other surgical or medical condition because based upon 
the organ type; it may take them up to 6 months to get to their steady state. Therefore, unlike 
previous studies (4-6, 21), our study, examined the hospitalization within first six months after 
LT.   
Our study did not find any association between race and early hospitalization rates. 
Consistent with previous studies (22, 23), our study found that African-American race was 
associated with a 38% increased risk of death after adjusting for recipient and donor factors. 
Historically, African-Americans have lower response rates to the peg-interferon based treatment. 
However, the conditional mortality model in our study was adjusted for hepatitis C. One study 
suggested that donor race mismatch in African Americans hepatitis C positive recipients affect 
survival; but this observation was not significant in African American hepatitis C negative 
recipients.(24) We did not explore the potentially complex relationship between donor-recipient 
mismatch and African-American race, with respect to post-LT survival; such analysis is outside 
the scope the objectives of our current report.  
The number of hospitalizations in the first 6 post-LT months, and being in the hospital at 
the 6-month post-LT point were easily the strongest predictors of mortality after adjusting for 
recipient and donor factors. Post-transplant outcomes, including patient survival and graft 
survival, are tracked by the Scientific Registry of Transplant Recipients (SRTR) and Centers for 
Medicare & Medicaid Services (CMS) using program-specific reports that are based upon 
recipient and donor characteristics. These regulatory tools ensure compliance with current 
performance standards for transplant programs.(25, 26) However, hospitalization rates are not 
included in the assessment of transplant programs.  
Wilson et al. combined the data from University Health Consortium and SRTR and 
showed a significant hospital-level variation in 30-day and 90-day readmission rates.(21)  While 
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we cannot modify most recipient and donor risk factors, knowledge of risk may result in process 
improvement that could identify LT recipients at risk for early hospitalization, stimulating more 
effective care-coordination and pre-emptive multidisciplinary management.  A recent pilot study 
by Russo et al. examined a prospective protocol designed to reduce readmission rates after LT by 
expanding outpatient services and alternatives to readmission. Under the protocol, LT recipients 
staying less than two midnights were considered as ‘observation status’ and not ‘inpatient 
readmission’. In their study of 46 patients after implementation of the protocol, readmission was 
reduced from 31% (pre-protocol) to 20%.(27) This change in the definition resulted in increase 
in the proportion of readmission as observation status (31% vs. 66%) during the protocol 
implementation time. However, this study did not examine the effect of these changes on patient 
mortality.(27, 28)  
Limitations of our study include the observational retrospective design that results in the 
potential for bias due to patient selection and unmeasured patient characteristics, use of Medicare 
as a primary or secondary payer that may not be generalizable to all LT recipients and missing 
data in the two administrative datasets that may affect the results.  It is very difficult to study the 
burden of hospitalization using single center data because of small sample size or using the 5% 
nationwide inpatient sample because LT are not very well represented in the dataset. We 
compared the baseline characteristics of LT recipients with Medicare as primary or secondary 
insurance to non-Medicare recipients, and except for slightly older age among those with 
Medicare as primary and secondary insurance, all other factors were similar. Missingness in this 
dataset varied from 0%-8%. Finally, our study cohort is from 2003-2010 but that does not limit 
the relevancy of our results since hepatitis C is still the leading indication for LT (18) and the 
majority of the LT candidates and recipients have detectable viral load at the time of LT.    
In conclusion, the burden of early hospitalization after liver transplantation is strongly 
associated with patient survival. Although not all post-LT hospitalization can be prevented, 
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treating hepatitis C with DAA while on the waiting list or after LT, good diabetes control and 
weight management along with developing effective multidisciplinary transitional care after 
hospitalization through ambulatory clinics may attenuate early post-LT hospitalization and 
resource utilization and improve survival. 
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Figure legends: 
Figure 1: Post-liver transplantation hospitalization rate by follow up time.  
 
Figure 2: Proportion of hospitalizations in the first 6 months after discharge from the liver transplantation 
hospitalization. 
 
Figure 3: Adjusted patient survival from incident model starting at time of discharge from index 
LT hospitalization.  
Footnote: Model was adjusted for recipient factors(non-ESRD, 59 years old, white, male with 
BMI 26.5, non-cholestatic liver disease, not on life support at LT, not in hospital at LT, non-
diabetic, slight ascites, not on dialysis with serum creatinine 1.0 mg/dl, bilirubin 2.9 mg/dl, 
albumin 2.9g/dl, INR 1.5, non-status 1, no portal vein thrombosis, no TIPSS) and donor factors 
(Donor age 44 years, Male donor, white donor, 172 cm tall, non-DCD, cause of death=trauma, 
whole liver, local transplant and 8 hours of cold ischemia time) 
 
Figure 4: Adjusted patient survival for various numbers of hospitalizations within first six 
months of LT from model conditional on survival at six months post-LT 
Footnote: Model was adjusted for recipient factors(non-ESRD, 59 years old, white, male with 
BMI 26.5, non-cholestatic liver disease, not on life support at LT, not in hospital at LT, non-
diabetic, slight ascites, not on dialysis with serum creatinine 1.0 mg/dl, bilirubin 2.9 mg/dl, 
albumin 2.9g/dl, INR 1.5, non-status 1, no portal vein thrombosis, no TIPSS) and donor factors 
(Donor age 44 years, Male donor, white donor, 172 cm tall, non-DCD, cause of death=trauma, 
whole liver, local transplant and 8 hours of cold ischemia time) 
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Table 1:  Characteristics of the cohort at LT 
Characteristic at LT 
Median (IQR) or n 
(%) 
(n=7,220) 
Age 59 (52-66) 
Female 2,428 (34%) 
Male 4,792 (66%) 
White 5,332 (74%) 
Black 550 (8%) 
Asian 276 (4%) 
Hispanic/Latino 985 (14%) 
Multi-racial/other 77 (1%) 
Status 1 at transplant 81 (1%) 
Body mass index (BMI) 27.8 (24.6-32.0) 
Hepatitis C 2,574 (36%) 
Cholestatic liver disease 526 (7%) 
Non-cholestatic liver disease 2,288 (32%) 
Hepatocellular carcinoma 1,228 (17%) 
Other liver disease 604 (8%) 
Lab MELD at transplant 17 (13-24) 
Albumin at transplant (g/dl) 2.9 (2.5-3.4) 
Diabetes 2,057 (28%) 
Dialysis 316 (4%) 
No ascites 1,346 (19%) 
Slight ascites 4,010 (56%) 
Moderate ascites 1,864 (26%) 
Portal vein thrombosis at transplant 546 (8%) 
History of TIPSS 768 (11%) 
In intensive care unit (ICU) at LT 504 (7%) 
Hospitalized, not in ICU 970 (13%) 
Not hospitalized 5,746 (80%) 
Renal risk index (RRI) 1.60 (0.99-2.84) 
Donor risk index (DRI) 1.45 (1.22-1.75) 
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Table 2: Recipient, donor and transplant factors: Multivariable model of early hospitalization 
 Factors 
Rate ratio (95% confidence 
interval) 
p-value 
Recipient factors 
Age (years) (ref. 18-39)  0.01* 
 40-49 0.91 (0.77, 1.07) 0.25 
 50-54 0.89 (0.75, 1.05) 0.15 
 55-59 0.81 (0.68, 0.95) 0.01 
 60-64 0.90 (0.76, 1.07) 0.25 
 ≥ 65 0.81 (0.69, 0.95) 0.01 
Female 1.16 (1.08, 1.23) <0.001 
Race  0.049* 
 African American 1.02 (0.91, 1.14) 0.75 
 Asian 0.80 (0.67, 0.96) 0.02 
 Hispanic/Latino 0.97 (0.88, 1.07) 0.56 
 Other race 0.74 (0.55, 1.00) 0.05 
BMI 1.00 (0.99, 1.00) 0.05 
Diagnosis  0.04* 
 Hepatitis C 1.12 (1.03, 1.21) 0.006 
 Cholestatic liver disease 1.04 (0.91, 1.19) 0.54 
 Hepatocellular carcinoma 1.05 (0.95, 1.16) 0.35 
 Other liver disease 0.96 (0.84, 1.10) 0.55 
On life support at LT 1.03 (0.84, 1.25) 0.79 
Medical Condition (ref. not 
hospitalized) 
 0.10 
 In ICU 0.98 (0.83, 1.15) 0.81 
 Hospitalized (not in ICU) 1.10 (1.00, 1.21) 0.05 
ESRD at baseline 1.24 (1.05, 1.47) 0.01 
Diabetes 1.18 (1.11, 1.26) <0.001 
On dialysis 1.29 (1.10, 1.52) 0.002 
Ascites (ref. none)  0.11* 
 Slight 1.09 (1.01, 1.19) 0.04 
 Moderate 1.07 (0.97, 1.18) 0.20 
Loge(creatinine) 1.22 (1.13, 1.31) <0.001 
Loge(bilirubin) 0.96 (0.92, 1.00) 0.06 
Loge(INR) 1.07 (0.96, 1.20) 0.24 
Loge(albumin) 0.83 (0.72, 0.95) 0.008 
Status 1 1.21 (0.90, 1.64) 0.21 
Portal vein thrombosis 0.96 (0.85, 1.08) 0.49 
TIPSS 1.10 (1.00, 1.21) 0.05 
Donor and transplant factors 
Age (years) (ref. 18-39)  0.19* 
 Under 18 1.01 (0.88, 1.14) 0.93 
 40-49 1.06 (0.97, 1.16) 0.19 
 50-59 1.11 (1.01, 1.21) 0.03 
 60-69 1.07 (0.96, 1.19) 0.19 
 70 or older 0.97 (0.84, 1.12) 0.67 
Female 0.95 (0.87, 1.03) 0.20 
Race (ref. Caucasian)  <0.001* 
 African American 1.11 (1.02, 1.21) 0.01 
 Asian 1.55 (1.27, 1.89) <0.001 
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 Factors 
Rate ratio (95% confidence 
interval) 
p-value 
 Hispanic/Latino 0.94 (0.86, 1.04) 0.26 
 Other race 0.73 (0.48, 1.11) 0.14 
Height (cm) 1.00 (0.99, 1.00) 0.18 
Donation after cardiac death 1.21 (1.05, 1.38) 0.007 
Cause of death (ref. all others)  0.27* 
 Anoxia 1.02 (0.94, 1.12) 0.60 
 Cardiovascular accident 1.07 (0.99, 1.15) 0.11 
Split liver 1.07 (0.83, 1.39) 0.58 
Donor location (ref. local)  0.44* 
 Regional share 1.00 (0.92, 1.09) 0.99 
 National share 1.09 (0.95, 1.24) 0.21 
Cold ischemia time (hours) 1.00 (0.99, 1.01) 0.68 
 
*p-value from overall test of significance for all levels of the factor. 
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Table 3: Predictors of post-LT mortality conditional upon 6 months survival after LT 
Factor 
Hazard ratio (95% 
confidence interval) p-value 
Number of early hospitalizations 1.22 (1.18, 1.27) <0.001 
In hospital at six months 2.32 (1.81, 2.97) <0.001 
Recipient Age (years) (ref. 18-39)  0.16* 
 40-49 0.85 (0.58, 1.26) 0.43 
 50-54 0.98 (0.67, 1.44) 0.92 
 55-59 1.00 (0.68, 1.47) 0.99 
 60-64 0.99 (0.66, 1.47) 0.96 
 65 or older 1.13 (0.78, 1.65) 0.51 
Female recipient 0.95 (0.83, 1.09) 0.46 
Recipient Race (ref. Caucasian)  <0.001* 
 African American 1.38 (1.11, 1.71) 0.004 
 Asian 1.11 (0.81, 1.52) 0.51 
 Hispanic/Latino 0.66 (0.53, 0.82) <0.001 
 Other race 0.97 (0.49, 1.92) 0.94 
Recipient BMI 0.99 (0.98, 1.00) 0.01 
Recipient diagnosis (ref. non-cholestatic liver disease)  <0.001* 
 Hepatitis C 1.59 (1.36, 1.86) <0.001 
 Cholestatic liver disease 0.75 (0.56, 1.01) 0.06 
 Hepatocellular carcinoma 1.69 (1.37, 2.07) <0.001 
 Other liver disease 0.85 (0.65, 1.10) 0.22 
Recipient on life support at LT 1.72 (1.07, 2.77) 0.02 
Recipient medical condition (ref. not hospitalized)  0.20* 
 In ICU 0.77 (0.52, 1.12) 0.17 
 Hospitalized (not in ICU) 1.09 (0.89, 1.33) 0.42 
Diabetes 1.06 (0.92, 1.21) 0.41 
ESRD at six months 1.85 (1.40, 2.46) <0.001 
On dialysis at LT 1.01 (0.70, 1.45) 0.97 
Ascites (ref. none)  0.95* 
 Slight 0.97 (0.82, 1.16) 0.77 
 Moderate 0.99 (0.80, 1.22) 0.92 
Loge(creatinine) 1.16 (1.00, 1.35) 0.06 
Loge(bilirubin) 0.99 (0.91, 1.07) 0.82 
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Factor 
Hazard ratio (95% 
confidence interval) p-value 
Loge(INR) 0.62 (0.48, 0.79) <0.001 
Loge(albumin) 0.62 (0.47, 0.82) <0.001 
Status 1 1.16 (0.60, 2.23) 0.66 
Portal vein thrombosis 0.94 (0.73, 1.22) 0.65 
TIPSS 1.14 (0.94, 1.39) 0.19 
Donor age (years) (ref. 18-39)  <0.001* 
 Under 18 0.98 (0.74, 1.28) 0.87 
 40-49 1.17 (0.98, 1.40) 0.09 
 50-59 1.44 (1.20, 1.73) <0.001 
 60-69 1.49 (1.20, 1.85) <0.001 
 70 or older 1.58 (1.21, 2.05) <0.001 
Female donor 0.97 (0.83, 1.14) 0.74 
Donor race (ref. Caucasian)  0.23* 
 African American 0.89 (0.75, 1.07) 0.21 
 Asian 1.23 (0.86, 1.76) 0.26 
 Hispanic/Latino 1.16 (0.95, 1.42) 0.15 
 Other race 1.12 (0.54, 2.30) 0.76 
Donor height (cm) 1.00 (0.99, 1.00) 0.46 
Donation after cardiac death 1.14 (0.86, 1.51) 0.37 
Donor cause of death (ref. all others)  0.08* 
 Anoxia 0.86 (0.71, 1.04) 0.11 
 Cardiovascular accident 0.85 (0.73, 0.99) 0.04 
Split liver 0.72 (0.39, 1.33) 0.30 
Donor location (ref. local)  0.12* 
 Regional share 1.19 (1.01, 1.41) 0.04 
 National share 1.12 (0.86, 1.45) 0.39 
Cold ischemia time (hours) 1.00 (0.98, 1.02) 0.87 
*p-value from overall test of significance for all levels of the factor. 
 
Page 26 of 30
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
  
 
 
Figure 1: Post-liver transplantation hospitalization rate by follow up time  
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Proportion of hospitalizations in the first 6 months after discharge from the liver transplantation 
hospitalization.  
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Figure 3: Adjusted patient survival from incident model starting at time of discharge from index LT 
hospitalization.  
 
254x190mm (300 x 300 DPI)  
Page 29 of 30
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
  
 
 
Figure 4: Adjusted patient survival for various numbers of hospitalizations within first six months of LT from 
model conditional on survival at six months post-LT  
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